5.08
-0.1(-1.93%)
Currency In USD
| Previous Close | 5.18 |
| Open | 5.19 |
| Day High | 5.19 |
| Day Low | 5.06 |
| 52-Week High | 12.7 |
| 52-Week Low | 3.32 |
| Volume | 17,381 |
| Average Volume | 24,873 |
| Market Cap | 187.26M |
| PE | -2.4 |
| EPS | -2.12 |
| Moving Average 50 Days | 5.62 |
| Moving Average 200 Days | 5.29 |
| Change | -0.1 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $258.52 as of December 22, 2024 at a share price of $5.08. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 2 years ago, it would be worth $781.54 as of December 22, 2024 at a share price of $5.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
GlobeNewswire Inc.
Dec 17, 2024 9:00 PM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
GlobeNewswire Inc.
Dec 08, 2024 5:00 PM GMT
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process with optimized dosing scheme to overcome target-media
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Nov 05, 2024 9:00 PM GMT
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing